GW&K Investment Management LLC lessened its stake in shares of Bruker Co. (NASDAQ:BRKR) by 1.8% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 114,823 shares of the medical research company’s stock after selling 2,123 shares during the period. GW&K Investment Management LLC owned 0.07% of Bruker worth $3,841,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of BRKR. Millennium Management LLC raised its holdings in Bruker by 15.2% in the 2nd quarter. Millennium Management LLC now owns 1,279,814 shares of the medical research company’s stock valued at $37,166,000 after buying an additional 168,597 shares during the period. Tdam USA Inc. raised its holdings in Bruker by 39.8% in the 3rd quarter. Tdam USA Inc. now owns 51,232 shares of the medical research company’s stock valued at $1,714,000 after buying an additional 14,575 shares during the period. Citadel Advisors LLC raised its holdings in Bruker by 1,883.2% in the 2nd quarter. Citadel Advisors LLC now owns 761,988 shares of the medical research company’s stock valued at $22,128,000 after buying an additional 723,566 shares during the period. Tower Research Capital LLC TRC purchased a new stake in Bruker in the 2nd quarter valued at about $467,000. Finally, Schwab Charles Investment Management Inc. raised its holdings in Bruker by 7.7% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 667,122 shares of the medical research company’s stock valued at $19,374,000 after buying an additional 47,728 shares during the period. Institutional investors and hedge funds own 64.87% of the company’s stock.

A number of analysts have issued reports on BRKR shares. Morgan Stanley lowered shares of Bruker from an “equal weight” rating to an “underweight” rating and boosted their price target for the stock from $31.00 to $32.00 in a research note on Thursday, September 20th. BidaskClub upgraded shares of Bruker from a “hold” rating to a “buy” rating in a research note on Friday, August 24th. ValuEngine upgraded shares of Bruker from a “hold” rating to a “buy” rating in a research note on Thursday, November 8th. UBS Group started coverage on shares of Bruker in a research note on Tuesday, October 9th. They set a “sell” rating and a $30.00 price target on the stock. They noted that the move was a valuation call. Finally, Zacks Investment Research upgraded shares of Bruker from a “hold” rating to a “strong-buy” rating and set a $38.00 price target on the stock in a research note on Monday, November 12th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $35.13.

Shares of Bruker stock traded down $1.41 on Friday, reaching $30.60. 1,269,997 shares of the company were exchanged, compared to its average volume of 540,457. Bruker Co. has a 1-year low of $28.13 and a 1-year high of $36.49. The company has a market cap of $5.01 billion, a PE ratio of 25.29, a P/E/G ratio of 1.95 and a beta of 1.39. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.32 and a current ratio of 2.24.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Thursday, November 1st. The medical research company reported $0.37 EPS for the quarter, topping the Zacks’ consensus estimate of $0.30 by $0.07. Bruker had a return on equity of 27.46% and a net margin of 5.24%. The business had revenue of $466.60 million during the quarter, compared to the consensus estimate of $451.88 million. During the same period in the previous year, the company posted $0.29 earnings per share. The business’s revenue for the quarter was up 7.1% on a year-over-year basis. On average, sell-side analysts predict that Bruker Co. will post 1.4 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 21st. Stockholders of record on Monday, December 3rd will be given a dividend of $0.04 per share. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.52%. The ex-dividend date of this dividend is Friday, November 30th. Bruker’s dividend payout ratio is presently 13.22%.

TRADEMARK VIOLATION NOTICE: “GW&K Investment Management LLC Trims Holdings in Bruker Co. (NASDAQ:BRKR)” was originally published by Marea Informative and is owned by of Marea Informative. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.mareainformativa.com/news/2018/12/08/bruker-co-brkr-holdings-cut-by-gwk-investment-management-llc-updated-updated-updated.html.

Bruker Profile

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Featured Article: Purposes and Functions of the Federal Reserve

Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.